gsk glp 1 agonist Glucagon-like peptide 1(GLP-1) receptor agonists in the management of the patient with type 2diabetes mellitus and chronic kidney disease: an approach for the nephrologist The promise of GLP-1 receptor

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

Our specialists empower patients with evidence-based strategies to engage in their overall health and achieve personal wellness goals

Liu, H., Zhan, Y

GLP-1 receptor agonists are emerging as a cornerstone in modern medicine, demonstrating proven benefits across metabolic, cardiovascular, and renal diseases

Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors

These findings highlighted retatrutides potential as a potent therapeutic agent for obesity and metabolic disorders